Adoptive cellular therapy after hematopoietic stem cell transplantation

被引：3

作者：

Vittayawacharin, Pongthep ^{[1
]}

Kongtim, Piyanuch ^{[1
]}

Chu, Yaya ^{[2
]}

June, Carl H. ^{[3
]}

Bollard, Catherine M. ^{[4
,5
]}

Ciurea, Stefan O. ^{[1
,6
]}

机构：

[1] Univ Calif Irvine, Dept Med, Hematopoiet Stem Cell Transplantat & Cellular Ther, Div Hematol Oncol, Orange, CA 92868 USA

[2] New York Med Coll, Dept Pediat, Valhalla, NY USA

[3] Univ Penn, Abramson Canc Ctr, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA USA

[4] Childrens Natl Hosp, Ctr Canc & Immunol Res, Washington, DC USA

[5] George Washington Univ, Washington, DC USA

[6] Univ Calif Irvine, Hematopoiet Stem cell Transplant & Cellular Therap, 101 City Dr S, Bldg 200, Rm 450, Orange, CA 92868 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 05期

关键词：

DONOR LYMPHOCYTE INFUSIONS; NATURAL-KILLER-CELLS; ACUTE MYELOID-LEUKEMIA; VERSUS-HOST-DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; CD34(+) PROGENITOR CELLS; MINIMAL RESIDUAL DISEASE; PROSPECTIVE PHASE-II; REGULATORY T-CELLS;

D O I：

10.1002/ajh.27204

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Effective cellular therapy using CD19 chimeric antigen receptor T-cells for the treatment of advanced B-cell malignancies raises the question of whether the administration of adoptive cellular therapy (ACT) posttransplant could reduce relapse and improve survival. Moreover, several early phase clinical studies have shown the potential beneficial effects of administration of tumor-associated antigen-specific T-cells and natural killer cells posttransplant for high-risk patients, aiming to decrease relapse and possibly improve survival. In this article, we present an in-depth review of ACT after transplantation, which has the potential to significantly improve the efficacy of this procedure and revolutionize this field. Summary of manufacturing processes for adoptive cellular therapies.image

引用

页码：910 / 921

页数：12

共 127 条

[81] MHC class I molecules and KIRs in human history, health and survival [J].

Parham, P .

NATURE REVIEWS IMMUNOLOGY, 2005, 5 (03) :201-214

[82] Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia [J].

Park, Jae H. ;

Riviere, Isabelle ;

Gonen, Mithat ;

Wang, Xiuyan ;

Senechal, Brigitte ;

Curran, Kevin J. ;

Sauter, Craig ;

Wang, Yongzeng ;

Santomasso, Bianca ;

Mead, Elena ;

Roshal, Mikhail ;

Maslak, Peter ;

Davila, Marco ;

Brentjens, Renier J. ;

Sadelain, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05) :449-459

[83] How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT [J].

Penack, Olaf ;

Peczynski, Christophe ;

Mohty, Mohamad ;

Yakoub-Agha, Ibrahim ;

Styczynski, Jan ;

Montoto, Silvia ;

Duarte, Rafael F. ;

Kroeger, Nicolaus ;

Schoemans, Helene ;

Koenecke, Christian ;

Peric, Zinaida ;

Basak, Grzegorz W. .

BLOOD ADVANCES, 2020, 4 (24) :6283-6290

[84] Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation [J].

Rizzieri, David A. ;

Storms, Robert ;

Chen, Dong-Feng ;

Long, Gwynn ;

Yang, Yiping ;

Nikcevich, Daniel A. ;

Gasparetto, Cristina ;

Horwitz, Mitchell ;

Chute, John ;

Sullivan, Keith ;

Hennig, Therese ;

Misra, Debashish ;

Apple, Christine ;

Baker, Megan ;

Morris, Ashley ;

Green, Patrick G. ;

Hasselblad, Vic ;

Chao, Nelson J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) :1107-1114

[85] Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study [J].

Roex, Marthe C. J. ;

van Balen, Peter ;

Germeroth, Lothar ;

Hageman, Lois ;

van Egmond, Esther ;

Veld, Sabrina A. J. ;

Hoogstraten, Conny ;

van Liempt, Ellis ;

Zwaginga, Jaap J. ;

de Wreede, Liesbeth C. ;

Meij, Pauline ;

Vossen, Ann C. T. M. ;

Danhof, Sophia ;

Einsele, Hermann ;

Schaafsma, M. Ron ;

Veelken, Hendrik ;

Halkes, Constantijn J. M. ;

Jedema, Inge ;

Falkenburg, J. H. Frederik .

LEUKEMIA, 2020, 34 (03) :831-844

[86] Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients [J].

Rooney, CM ;

Smith, CA ;

Ng, CYC ;

Loftin, SK ;

Sixbey, JW ;

Gan, YJ ;

Srivastava, DK ;

Bowman, LC ;

Krance, RA ;

Brenner, MK ;

Heslop, HE .

BLOOD, 1998, 92 (05) :1549-1555

[87] USE OF GENE-MODIFIED VIRUS-SPECIFIC T-LYMPHOCYTES TO CONTROL EPSTEIN-BARR-VIRUS-RELATED LYMPHOPROLIFERATION [J].

ROONEY, CM ;

SMITH, CA ;

NG, CYC ;

LOFTIN, S ;

LI, CF ;

KRANCE, RA ;

BRENNER, MK ;

HESLOP, HE .

LANCET, 1995, 345 (8941) :9-13

[88] Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants [J].

Ruggeri, L ;

Capanni, M ;

Urbani, E ;

Perruccio, K ;

Shlomchik, WD ;

Tosti, A ;

Posati, S ;

Rogaia, D ;

Frassoni, F ;

Aversa, F ;

Martelli, MF ;

Velardi, A .

SCIENCE, 2002, 295 (5562) :2097-2100

[89] Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation [J].

Ruggeri, L ;

Capanni, M ;

Casucci, M ;

Volpi, I ;

Tosti, A ;

Perruccio, K ;

Urbani, E ;

Negrin, RS ;

Martelli, MF ;

Velardi, A .

BLOOD, 1999, 94 (01) :333-339

[90] Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation [J].

Russell, NH ;

Byrne, JL ;

Faulkner, RD ;

Gilyead, M ;

Das-Gupta, EP ;

Haynes, AP .

BONE MARROW TRANSPLANTATION, 2005, 36 (05) :437-441

← 4 5 6 7 8 9 10 11 12 13 →